Nevro Corp., was founded in 2006 ... Yes, we’ve made enormous strides—waveforms have advanced, remote programming is here, and IPGs are smaller with improved battery life and longevity. But none of ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...

The company made another M&A play this month with its planned acquisition of spinal cord stimulation (SCS) company Nevro. “I’m proud of our team at Globus Medical, delivering incredible ...

Nevro has a beta of 0.91 ... HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion ...

Shares of NYSE NVRO opened at $5.72 on Tuesday. The company has a fifty day moving average price of $4.48 and a 200 day moving average price of $4.98. The firm has a market cap of $214.14 million ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the transaction. Under the terms of the agreement, Globus Medical will pay ...

On February 7, 2025, Nevro Corp was acquired by Globus Medical (NYSE:GMED) in an all-cash transaction valuing NVRO at $5.85 per share, representing a total equity value of approximately $250 million.

Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market ...